Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

(2011) Ludwig Kappos et al.   LANCET NEUROLOGY

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

(2011) M. Cossburn et al.   NEUROLOGY

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Rituximab for severe myasthenia gravis - experience from five patients

(2010) C. Lindberg et al.   ACTA NEUROLOGICA SCANDINAVICA

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

(2010) Richard A. Rudick et al.   ANNALS OF NEUROLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

Assay design and sample collection can affect anti-John Cunningham virus antibody detection

(2010) Susan E. Goelz et al.   ANNALS OF NEUROLOGY

Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis

(2010) Laura Piccio et al.   ARCHIVES OF NEUROLOGY

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

(2010) Mikkel Østergaard et al.   ARTHRITIS AND RHEUMATISM

New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies

(2010) Tadeusz Robak et al.   BIODRUGS

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist rituximab-mediated lysis

(2010) T. van Meerten et al.   HAEMATOLOGICA

Successful Treatment with Rituximab in a Patient with Stiff-Person Syndrome Complicated by Dysthyroid Ophthalmopathy

(2010) Nagaaki Katoh et al.   INTERNAL MEDICINE

Stiff-Person Syndrome

(2010) Eugene A. Bacorro et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis

(2010) J.L. Dupond et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies

(2010) Bruce D. Cheson   JOURNAL OF CLINICAL ONCOLOGY

Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians

(2010) A. Antonsson et al.   JOURNAL OF GENERAL VIROLOGY

JCV detection in multiple sclerosis patients treated with natalizumab

(2010) Saud A. Sadiq et al.   JOURNAL OF NEUROLOGY

The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome

(2010) P. Maddison et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Pediatric Dosing of Rituximab Revisited: Serum Concentrations in Opsoclonus-myoclonus Syndrome

(2010) Michael R. Pranzatelli et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study

(2010) Samantha Jilek et al.   LANCET NEUROLOGY

The Complex Clinical Picture of Side Effects to Biologicals

(2010) Oliver V. Hausmann et al.   MEDICAL CLINICS OF NORTH AMERICA

B cell depletion therapy for new-onset opsoclonus-myoclonus

(2010) Michael R. Pranzatelli et al.   MOVEMENT DISORDERS

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial

(2010) R. T. Naismith et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

Primary central nervous system lymphoma in a patient treated with natalizumab

(2009) Andreas Schweikert et al.   ANNALS OF NEUROLOGY

Natalizumab and central nervous system lymphoma: No clear association

(2009) Carmen Bozic et al.   ANNALS OF NEUROLOGY

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

(2009) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Monozygotic twins with stiff person syndrome and autoimmune thyroiditis: rituximab inefficacy in a double-blind, randomised, placebo controlled crossover study

(2009) N Venhoff et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis

(2009) Bibiana Bielekova et al.   ARCHIVES OF NEUROLOGY

Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)

(2009) B. De Angelis et al.   BLOOD

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis

(2009) M. C. Dalakas et al.   BRAIN

Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

(2009) Erin E Longbrake et al.   Expert Review of Neurotherapeutics

Long-Term Cerebrospinal Fluid and Blood Lymphocyte Dynamics After Rituximab for Pediatric Opsoclonus-Myoclonus

(2009) Michael R. Pranzatelli et al.   JOURNAL OF CLINICAL IMMUNOLOGY

B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

(2009) Sara A. J. Thompson et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors

(2009) Adrian Egli et al.   JOURNAL OF INFECTIOUS DISEASES

α4-Integrin antagonism with natalizumab

(2009) Olaf Stüve et al.   JOURNAL OF NEUROLOGY

Glatiramer acetate treatment in PPMS: Why males appear to respond favorably

(2009) Jerry S. Wolinsky et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

(2009) Kenneth R Carson et al.   LANCET ONCOLOGY

Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating

(2009) Kenneth R. Carson et al.   LEUKEMIA & LYMPHOMA

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

(2009) C Pena-Rossi et al.   LUPUS

Daclizumab in treatment of multiple sclerosis patients

(2009) EN Ali et al.   Multiple Sclerosis Journal

Rituximab in the management of refractory myasthenia gravis

(2009) Nazlee Zebardast et al.   MUSCLE & NERVE

Atacicept bei Multipler Sklerose

(2009) H.-P. Hartung   NERVENARZT

GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study

(2009) A. D. Goodman et al.   NEUROLOGY

OCULAR TOXOPLASMOSIS DURING NATALIZUMAB TREATMENT

(2009) C. Zecca et al.   NEUROLOGY

Biology and treatment of primary central nervous system lymphoma

(2009) Alain P. Algazi et al.   Neurotherapeutics

Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab

(2009) Yiping Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Seroepidemiology of Human Polyomaviruses

(2009) Jaime M. Kean et al.   PLoS Pathogens

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Treatment of Neuromyelitis Optica With Rituximab

(2008)   ARCHIVES OF NEUROLOGY

Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab

(2008) Maria del Pilar Martin   ARCHIVES OF NEUROLOGY

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

(2008) A. Hagenbeek et al.   BLOOD

Antibody Engineering Principles and Applications

(2008) LiNa Loo et al.   CANCER JOURNAL

Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use

(2008) G. Calogiuri et al.   CURRENT PHARMACEUTICAL DESIGN

A review of the current use of rituximab in autoimmune diseases

(2008) Hakan M. Gürcan et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis

(2008) Ivan Nestorov et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients

(2008) Raija L.P. Lindberg et al.   JOURNAL OF NEUROIMMUNOLOGY

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) G Comi et al.   LANCET

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis

(2008) John T. Mullen et al.   NEW ENGLAND JOURNAL OF MEDICINE

More on Melanoma with Transdifferentiation

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

RESPONSE TO RITUXIMAB AND PREDNISOLONE FOR OPSOCLONUS-MYOCLONUS-ATAXIA SYNDROME IN A CHILD WITH GANGLIONEUROBLASTOMA

(2008) Funda Corapcioglu et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Rituximab and Intravenous Immunoglobulins for Relapsing Postinfectious Opsoclonus-Myoclonus Syndrome

(2008) Wilhelmina G. Leen et al.   PEDIATRIC NEUROLOGY

The Biology of Interleukin-2

(2007) Thomas R. Malek   Annual Review of Immunology

Treatment of neuroblastoma-related opsoclonus–myoclonus–ataxia syndrome with high-dose dexamethasone pulses

(2007) Florian Ertle et al.   PEDIATRIC BLOOD & CANCER

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma

(2006) Michael J. Burke et al.   PEDIATRIC BLOOD & CANCER